TY - JOUR
T1 - Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer
AU - Inoue, Yasuhiro
AU - Iwata, Takashi
AU - Okugawa, Yoshinaga
AU - Kawamoto, Aya
AU - Hiro, Junichiro
AU - Toiyama, Yuji
AU - Tanaka, Koji
AU - Uchida, Keiichi
AU - Mohri, Yasuhiko
AU - Miki, Chikao
AU - Kusunoki, Masato
PY - 2012/12
Y1 - 2012/12
N2 - Objectives: The inflammation-based Glasgow Prognostic Score (GPS) is associated with outcome in a variety of cancers. This study investigated whether a modified GPS (mGPS) could predict survival in patients undergoing multimodality therapy for advanced colorectal cancer (CRC). Methods: We enrolled 245 patients with advanced CRC who received chemotherapy. The mGPS was recorded prior to first-line chemotherapy and to cytoreductive therapy including secondary surgery and/or radiofrequency ablation. The prognostic significance of the mGPS was analyzed using Kaplan-Meier, univariate, and multivariate analyses. Results: In patients who received chemotherapy alone (n = 163), the mGPS prior to chemotherapy was an independent prognostic indicator of survival [odds ratio (OR) 1.858; 95% confidence interval (CI) 1.213-2.846; p = 0.0044]. In patients who also underwent cytoreductive therapy (n = 82), the mGPS decreased after chemotherapy in 22 patients (27%) and increased in 5 (6%). In these patients, the mGPS prior to cytoreductive therapy was an independent prognostic indicator of survival (OR 3.412; 95% CI 1.198-9.720; p = 0.0216), but the mGPS prior to chemotherapy was not. Conclusions: The mGPS is an independent prognostic indicator of survival in patients undergoing multimodality therapy for advanced CRC, if recorded at a relevant time point.
AB - Objectives: The inflammation-based Glasgow Prognostic Score (GPS) is associated with outcome in a variety of cancers. This study investigated whether a modified GPS (mGPS) could predict survival in patients undergoing multimodality therapy for advanced colorectal cancer (CRC). Methods: We enrolled 245 patients with advanced CRC who received chemotherapy. The mGPS was recorded prior to first-line chemotherapy and to cytoreductive therapy including secondary surgery and/or radiofrequency ablation. The prognostic significance of the mGPS was analyzed using Kaplan-Meier, univariate, and multivariate analyses. Results: In patients who received chemotherapy alone (n = 163), the mGPS prior to chemotherapy was an independent prognostic indicator of survival [odds ratio (OR) 1.858; 95% confidence interval (CI) 1.213-2.846; p = 0.0044]. In patients who also underwent cytoreductive therapy (n = 82), the mGPS decreased after chemotherapy in 22 patients (27%) and increased in 5 (6%). In these patients, the mGPS prior to cytoreductive therapy was an independent prognostic indicator of survival (OR 3.412; 95% CI 1.198-9.720; p = 0.0216), but the mGPS prior to chemotherapy was not. Conclusions: The mGPS is an independent prognostic indicator of survival in patients undergoing multimodality therapy for advanced CRC, if recorded at a relevant time point.
UR - http://www.scopus.com/inward/record.url?scp=84868603083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868603083&partnerID=8YFLogxK
U2 - 10.1159/000343822
DO - 10.1159/000343822
M3 - Article
C2 - 23147449
AN - SCOPUS:84868603083
SN - 0030-2414
VL - 84
SP - 100
EP - 107
JO - Oncology (Switzerland)
JF - Oncology (Switzerland)
IS - 2
ER -
